Calcineurin-inhibitor-sparing immunosuppressive protocols.

Area of Science:

• Nephrology
• Transplantation Immunology

Background:

• Calcineurin inhibitors (CNI) are crucial for improving graft survival in renal transplantation.
• However, managing CNI-related nephrotoxicity alongside preventing immunologic allograft loss remains a significant clinical challenge.

Purpose of the Study:

• To review and discuss CNI-sparing strategies in renal transplantation.
• To evaluate the efficacy and safety of CNI minimization, withdrawal, and avoidance.

Main Methods:

• Review of existing literature on CNI-sparing protocols.
• Analysis of outcomes associated with mycophenolate mofetil (MMF), mTOR inhibitors (e.g., sirolimus), and induction therapies (e.g., anti-IL-2R).
• Comparison of CNI-sparing approaches versus traditional CNI-based regimens.

Main Results:

• CNI minimization with MMF can improve renal function without increasing rejection.
• CNI withdrawal, particularly with MMF or sirolimus, shows potential for stabilizing or improving renal function and graft survival, though acute rejection is a risk.
• CNI avoidance strategies are evolving, with some protocols showing promise but others facing challenges with infection rates or acute rejection.

Conclusions:

• Newer immunosuppressive agents have made CNI minimization, withdrawal, and avoidance feasible in renal transplantation.
• These strategies offer potential to mitigate CNI-induced nephrotoxicity while maintaining adequate immunosuppression.
• Further research into novel agents like costimulation blockers may facilitate the development of safe, CNI-free regimens.